Article info

Download PDFPDF
CP-150 Evaluation of infliximab (REMICADE) substitution by infliximab biosimilar (INFLECTRA): cost savings and therapeutic maintenance

Authors

Citation

Gutermann L, Apparuit M, Boissinot L working group TSIC, et al
CP-150 Evaluation of infliximab (REMICADE) substitution by infliximab biosimilar (INFLECTRA): cost savings and therapeutic maintenance

Publication history

  • First published February 25, 2017.
Online issue publication 
February 25, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.